-
-
-
-
-
-
-
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces Restructuring and Cost Reduction Plan to Address Market Dynamics
-
-
-
-
-
-
-
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
-
-
-
-
-
-
-
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Highlights Progress in Pain Management and CINV Franchises
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces FDA Acceptance of NDA Resubmission for HTX-011 for Management of Postoperative Pain
-
-
-
-
-
-
-
Bullish Options Positioning in Heron Therapeutics (HRTX) Targets Upside Through May Ahead of HTX-011 PDUFA Review Apr. 30th Due Date -Susquehanna
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

